Trial | NCT03083119  Report issue

Title

Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina
The Methylation Regulation Mechanism of Blood Stasis Relevant miRNA Expression on Coronary Heart Disease

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    70
In this study, typical cases of coronary heart disease are selected. They will be intervened by Xuesaitong soft capsules to investigate efficacy and safety for Coronary Heart disease.
Study Started
Mar 20
2017
Anticipated
Primary Completion
Apr 20
2017
Anticipated
Study Completion
Aug 20
2017
Anticipated
Last Update
Mar 17
2017

Drug Xuesaitong soft capsule

Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.

Drug Placebo oral capsule

Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.

Xuesaitong soft capsule group Experimental

Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.

Placebo Comparator Placebo Comparator

Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.

Criteria 

Inclusion Criteria:

Clinical diagnosis of coronary angiography unstable angina
Clinical diagnosis of unstable angina
Age of 30 to 75 years old
Not use thrombolysis, dilate coronary drugs within two weeks
Sign the consent

Exclusion Criteria:

Severe valvular heart disease
Insulin-dependent diabetes
mental disease
Combined with severe liver, kidney, hematopoietic system disorder
Patients with malignant tumors
Pregnancy or breast-feeding women
Recent history of trauma
Drug allergy
No Results Posted